礼来拟与香港生物科技公司英矽智能达成20亿美元AI药物开发协议

投资观察03-29

据《金融时报》报道，美国制药巨头礼来公司即将与香港生物技术公司英矽智能签署一项价值高达20亿美元的合作协议，共同开发人工智能驱动的药物。

该协议的核心内容是，礼来公司将获得英矽智能旗下一款用于治疗糖尿病的GLP-1药物的独家销售权。此次合作凸显了大型制药企业正日益借助人工智能技术来加速创新疗法的研发进程。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1126088383?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-29 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126088383","market":"us","top_or_hot":-1,"title":"礼来拟与香港生物科技公司英矽智能达成20亿美元AI药物开发协议","media":"投资观察","content":"<p>据《金融时报》报道，美国制药巨头礼来公司即将与香港生物技术公司英矽智能签署一项价值高达20亿美元的合作协议，共同开发人工智能驱动的药物。</p>\n<p>该协议的核心内容是，礼来公司将获得英矽智能旗下一款用于治疗糖尿病的GLP-1药物的独家销售权。此次合作凸显了大型制药企业正日益借助人工智能技术来加速创新疗法的研发进程。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来拟与香港生物科技公司英矽智能达成20亿美元AI药物开发协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来拟与香港生物科技公司英矽智能达成20亿美元AI药物开发协议\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-29 19:16 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据《金融时报》报道，美国制药巨头礼来公司即将与香港生物技术公司英矽智能签署一项价值高达20亿美元的合作协议，共同开发人工智能驱动的药物。\n该协议的核心内容是，礼来公司将获得英矽智能旗下一款用于治疗糖尿病的GLP-1药物的独家销售权。此次合作凸显了大型制药企业正日益借助人工智能技术来加速创新疗法的研发进程。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1126088383","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126088383","pubTimestamp":1774782989,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"据《金融时报》报道，美国制药巨头礼来公司即将与香港生物技术公司英矽智能签署一项价值高达20亿美元的合作协议，共同开发人工智能驱动的药物。\n该协议的核心内容是，礼来公司将获得英矽智能旗下一款用于治疗糖尿病的GLP-1药物的独家销售权。此次合作凸显了大型制药企业正日益借助人工智能技术来加速创新疗法的研发进程。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03696":"英矽智能","BK1141":"生命科学工具和服务"},"translate_title":"Eli Lilly plans to reach $2 billion AI drug development agreement with Hong Kong biotech company Insilicon Intelligent","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"据《金融时报》报道，美国制药巨头礼来公司即将与香港生物技术公司英矽智能签署一项价值高达20亿美元的合作协议，共同开发人工智能驱动的药物。\n该协议的核心内容是，礼来公司将获得英矽智能旗下一款用于治疗糖尿病的GLP-1药物的独家销售权。此次合作凸显了大型制药企业正日益借助人工智能技术来加速创新疗法的研发进程。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126088383","isCrawlerRequest":true}